Literature DB >> 30519966

Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients.

Giovanni Mazzola1, Lucia Adamoli1, Vincenza Calvaruso2, Fabio Salvatore Macaluso3, Pietro Colletti1, Sergio Mazzola4, Adriana Cervo1, Marcello Trizzino1, Francesco Di Lorenzo5, Chiara Iaria5, Tullio Prestileo5, Ambrogio Orlando6, Vito Di Marco2, Antonio Cascio1.   

Abstract

PURPOSE: We aimed to assess the diagnostic reliability of two indirect biomarkers, APRI and FIB-4, for the staging of liver fibrosis using transient elastography (TE) as reference standard, among HIV/HCV co-infected and HCV mono-infected patients.
METHODS: This is an observational, retrospective study on subjects who had access to the RESIST HCV from October 2013 to December 2016, a regional network encompassing 22 hospitals and academic centers throughout Sicily. Sensitivity, specificity and diagnostic accuracy of indirect biomarkers for liver stiffness measurement (LSM) < 9.5 kPa (significant fibrosis) and LSM ≥ 12.5 kPa (cirrhosis) were determined by receiver operator characteristics (ROC) curves.
RESULTS: 238 HIV/HCV co-infected and 1937 HCV mono-infected patients were included. Performances of FIB-4 and APRI for the detection of significant fibrosis and cirrhosis proved to be unsatisfactory, with very high false negative and false positive rates among both cohorts. No significant differences were found after stratification of HIV/HCV co-infected patients for BMI < or ≥ 25, ALT < or ≥ 40 IU/L, ALT < or ≥ 80 IU/L, and presence/absence of a bright liver echo pattern on ultrasonography.
CONCLUSIONS: Differently from other studies, we detected the unreliability of APRI and FIB-4 for the assessment of liver fibrosis in both HCV mono-infected and HIV/HCV co-infected patients.

Entities:  

Keywords:  APRI; FIB-4; HCV; HIV; Noninvasive biomarkers; Transient elastography

Mesh:

Substances:

Year:  2018        PMID: 30519966     DOI: 10.1007/s15010-018-1258-6

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  23 in total

1.  Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes.

Authors:  J Macías; J A Girón-González; M González-Serrano; D Merino; P Cano; J A Mira; A Arizcorreta-Yarza; J Ruíz-Morales; J M Lomas-Cabeza; J A García-García; J E Corzo; J A Pineda
Journal:  Gut       Date:  2005-08-23       Impact factor: 23.059

2.  The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection.

Authors:  George N Ioannou; Christopher L Bryson; Noel S Weiss; Richard Miller; John D Scott; Edward J Boyko
Journal:  Hepatology       Date:  2013-01       Impact factor: 17.425

3.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.

Authors:  Richard K Sterling; Eduardo Lissen; Nathan Clumeck; Ricard Sola; Mendes Cassia Correa; Julio Montaner; Mark S Sulkowski; Francesca J Torriani; Doug T Dieterich; David L Thomas; Diethelm Messinger; Mark Nelson
Journal:  Hepatology       Date:  2006-06       Impact factor: 17.425

4.  Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study.

Authors:  J M Miro; M Montejo; L Castells; A Rafecas; S Moreno; F Agüero; M Abradelo; P Miralles; J Torre-Cisneros; J D Pedreira; E Cordero; G de la Rosa; B Moyano; A Moreno; I Perez; A Rimola
Journal:  Am J Transplant       Date:  2012-04-04       Impact factor: 8.086

5.  Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration.

Authors:  L Castera; M Winnock; E Pambrun; V Paradis; P Perez; M-A Loko; J Asselineau; F Dabis; F Degos; D Salmon
Journal:  HIV Med       Date:  2013-09-06       Impact factor: 3.180

Review 6.  Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis.

Authors:  Zhong-Hua Lin; Yong-Ning Xin; Quan-Jiang Dong; Qing Wang; Xiang-Jun Jiang; Shu-Hui Zhan; Ying Sun; Shi-Ying Xuan
Journal:  Hepatology       Date:  2011-02-11       Impact factor: 17.425

Review 7.  Nonalcoholic fatty liver disease and HIV infection.

Authors:  Anaïs Vallet-Pichard; Vincent Mallet; Stanislas Pol
Journal:  Semin Liver Dis       Date:  2012-07-03       Impact factor: 6.115

8.  A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

Authors:  Chun-Tao Wai; Joel K Greenson; Robert J Fontana; John D Kalbfleisch; Jorge A Marrero; Hari S Conjeevaram; Anna S-F Lok
Journal:  Hepatology       Date:  2003-08       Impact factor: 17.425

9.  Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus.

Authors:  Juan Macías; Juan Berenguer; Miguel A Japón; José A Girón; Antonio Rivero; Luis F López-Cortés; Ana Moreno; Mercedes González-Serrano; José A Iribarren; Enrique Ortega; Pilar Miralles; José A Mira; Juan A Pineda
Journal:  Hepatology       Date:  2009-10       Impact factor: 17.425

Review 10.  Metabolic factors and chronic hepatitis C: a complex interplay.

Authors:  Fabio Salvatore Macaluso; Marcello Maida; Maria Giovanna Minissale; Teresa Li Vigni; Simona Attardo; Emanuele Orlando; Salvatore Petta
Journal:  Biomed Res Int       Date:  2013-07-17       Impact factor: 3.411

View more
  2 in total

1.  Enzymatic liver function measured by LiMAx - a reliable diagnostic and prognostic tool in chronic liver disease.

Authors:  Matthias Buechter; Sarah Kersting; Guido Gerken; Alisan Kahraman
Journal:  Sci Rep       Date:  2019-09-19       Impact factor: 4.379

2.  Diagnostic performance of APRI and FIB-4 for confirming cirrhosis in Indonesian HIV/HCV co-infected patients.

Authors:  Evy Yunihastuti; Bramantya Wicaksana; Andrian Wiraguna; Ainum Jhariah Hidayah; Fhadilla Amelia; Veritea Natali; Alvina Widhani; Andri Sanityoso Sulaiman; Juferdy Kurniawan
Journal:  BMC Infect Dis       Date:  2020-05-25       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.